BD FACSAria II for NJMS Flow Cytometry Core

用于 NJMS 流式细胞术核心的 BD FACSAria II

• 批准号: 8052153
• 负责人: PATRICIA FITZGERALD-BOCARSLY
• 金额: $ 50.08万
• 依托单位: UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-01 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8052153
• 关键词: 11 year old; Advisory Committees; Aerosols; Applications Grants; Area; Biological; Biology; Cardiovascular system; Cell Count; Cell Line; Cells; Cellular biology; Commit; Communities; Contract Services; Deposition; Fees; Flow Cytometry; Funding; Grant; HIV; Housing; Human; Immunology; Infectious Disease Immunology; Institutes; Laboratories; Lasers; Life; Lupus; Minor; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of General Medical Sciences; National Institute of Mental Health; Natural Immunity; New Jersey; Parasites; Productivity; Radiobiology; Recruitment Activity; Refrigeration; Request for Applications; Research; Research Personnel; Safety; Sampling; Science; Slide; Sorting - Cell Movement; Structure; Technology; Temperature; Time; United States National Institutes of Health; Universities; Work; cancer cell; cost; cytokine; experience; instrument; instrumentation; interest; medical schools; meetings; pathogen; stem cell biology

DESCRIPTION (provided by applicant): This Shared Instrumentation Grant (SIG) application requests funds for the purchase of a state-of-the-art Becton-Dickinson FACSAria II cell sorter to be located in the Flow Cytometry Core Laboratory at the New Jersey Medical School. The FACSAria II cell sorter has numerous advantages over the 11 year-old, technologically outdated FACSVantage it will replace. Most importantly, the FACSAria II is a compact, desk- top sorter that can be placed in a Baker BioPROTect III class II biological safety cabinet, which is also requested in this proposal. The FACSAria II will be equipped with the aerosol management option for added operator protection. These features are essential to the majority of our users who need to sort either live human cells and cell lines or live, pathogen-infected cells, including HIV-infected cells; these projects cannot currently be carried out using the FACSVantage, which lacks these safety features. Additional features of the instrument that are necessary for our SIG investigators include four-way sorting, four lasers (355 nm (UV), 488 nm, 561nm and 640 nm) with the capability of detecting up to 14 parameters, a temperature control option for refrigeration and cooling of the pre- and post-sort samples, and an automatic cell deposition unit for desposition of fixed numbers of cells into plates or onto slides. The FACSAria has additional advantages over the FACSVantage that will benefit all of our users: it is faster and more efficient and its housing in the BioPROtect III will facilitate aseptic sorts. This application is supported by projects submitted by 10 major users and 9 minor users; the lasers and accessories were chosen to meet the sorting needs of this very diverse group of investigators. While a number of the investigators work in the area of infectious disease immunology, including, e.g., HIV immunology, parasite immunology, innate immunity, and cytokines, other investigators work in diverse areas such as cancer cell biology, stem cell biology, radiation biology, cardiovascular biology and lupus. This diversity in research interests is reflected in the fact that these SIG investigators are funded by six different institutes at the NIH: the NIAID, NCI, NIGMS, NIDDK, NHBLI and NIMH. All of these investigators extensively use flow cytometry in their studies, and nearly all have significant experience with sorting. There is strong institutional commitment to this FACSAria application: the medical school has committed ongoing funds for a full-time operator and service contract for the instrument. These costs will be offset, in part, by users fees from the SIG investigators and other investigators recruited to utilize this powerful technology. The FACSAria will be supported by a strong administrative structure including oversight by the Flow Cytometry Core Advisory Committee, which is chaired by the SIG PI, Dr. Fitzgerald-Bocarsly, who is also the Scientific Director of the Flow Cytometry and Immunology Core Laboratory. Overall, the introduction of this FACSAria II to our university community is expected to greatly enhance our investigators' productivity and contribution to biomedical science.

描述（由申请人提供）：此共享的仪器赠款（SIG）申请要求购买最先进的Becton-Dickinson Facsaria II细胞分隔器，该基础位于新泽西州医学院的流式细胞仪核心实验室中。 Facsaria II细胞分系程序比将取代的11岁，技术过时的FACSVantage具有许多优势。最重要的是，Facsaria II是一个紧凑的台式分系程序，可以放置在Baker Biopotect III II类生物安全柜中，该提案也可以在此提案中进行。 Facsaria II将配备Aerosol Management选项，以增加操作员保护。这些特征对于需要分类活细胞和细胞系或活病原体感染的细胞（包括HIV感染的细胞）的大多数用户至关重要。这些项目目前无法使用FACSVantage进行，该项目缺乏这些安全功能。我们的SIG调查人员所需的仪器的其他功能包括四个方向分类，四个激光器（355 nm（紫外线），488 nm，561nm和640 nm），能够检测多达14个参数，温度控制选项，用于固定和固定型单元的固定型和固定型单元的固定型和固定型单元的温度控制选项。 FACSARIA在FACSVantage上具有其他优势，这将使我们所有的用户受益：它更快，更有效，其生物保护区III中的住房将有助于无菌性。该应用程序由10个主要用户和9个未成年人提交的项目支持；选择激光和配件以满足这个非常多样化的调查人员的分类需求。尽管许多研究人员在传染病免疫学领域工作，例如，例如HIV免疫学，寄生虫免疫学，先天免疫和细胞因子，但其他研究者在癌症细胞生物学，干细胞生物学，放射生物学，心血管生物学和狼疮等各个领域工作。这些SIG研究人员由NIH的六个不同机构资助：NIAID，NCI，NIGMS，NIGMS，NIDDK，NHBLI和NIMH资助了研究兴趣的多样性。所有这些研究者在研究中广泛使用流式细胞仪，几乎所有人都有分类的丰富经验。对此FACSARIA申请的机构承诺有很大的承诺：医学院已为该工具的全职运营商和服务合同提供了持续的资金。这些费用将部分抵消SIG调查人员的用户费用和其他招募来利用这项强大技术的调查人员的费用。 Facsaria将得到强大的行政结构的支持，包括流式细胞仪核心咨询委员会的监督，该核心咨询委员会由SIG PI主持，Fitzgerald-Bocarsly博士也是流式细胞仪和免疫学核心实验室的科学总监。总体而言，预计该Facsaria II向我们的大学社区的引入将极大地提高我们的研究人员对生物医学科学的贡献。

项目成果

A transmissible γδ intraepithelial lymphocyte hyperproliferative phenotype is associated with the intestinal microbiota and confers protection against acute infection.

• DOI: 10.1038/s41385-022-00522-x
• 发表时间: 2022-04
• 期刊: MUCOSAL IMMUNOLOGY
• 影响因子: 8
• 作者: Jia, Luo;Wu, Guojun;Alonso, Sara;Zhao, Cuiping;Lemenze, Alexander;Lam, Yan Y.;Zhao, Liping;Edelblum, Karen L.
• 通讯作者: Edelblum, Karen L.

γδ Intraepithelial Lymphocytes Facilitate Pathological Epithelial Cell Shedding Via CD103-Mediated Granzyme Release.

• DOI: 10.1053/j.gastro.2021.11.028
• 发表时间: 2022-03
• 期刊: Gastroenterology
• 影响因子: 29.4
• 作者: Hu MD;Golovchenko NB;Burns GL;Nair PM;Kelly TJ 4th;Agos J;Irani MZ;Soh WS;Zeglinski MR;Lemenze A;Bonder EM;Sandrock I;Prinz I;Granville DJ;Keely S;Watson AJM;Edelblum KL
• 通讯作者: Edelblum KL